1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
August 2016 in “Journal of Investigative Dermatology”
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”
14 citations
,
April 2009 in “Acta Medica Scandinavica” Minoxidil helps control blood pressure but has side-effects, so it's not for everyone.
13 citations
,
August 2013 in “Journal of pharmaceutical sciences” Researchers created a skin patch that delivers two drugs for treating enlarged prostate, which may improve patient use and dosage control.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
November 2021 in “OPAL (Open@LaTrobe) (La Trobe University)” Melatonin may treat rosacea and Alzheimer's by reducing inflammation and affecting blood vessel growth.
20 citations
,
August 2020 in “Stem Cell Research & Therapy” miR-150 helps blood vessel cells develop and speeds up blood clot healing.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
40 citations
,
July 2011 in “The journal of clinical hypertension” Hydralazine and minoxidil are blood pressure medications that relax blood vessels, with potential side effects like rapid heartbeat and fluid retention, and are used for severe or pregnancy-related hypertension.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
96 citations
,
October 1981 in “Drugs” Minoxidil effectively treats severe hypertension but may cause side effects, so careful monitoring is needed.
April 2022 in “Anti-cancer agents in medicinal chemistry” Some existing medicines show promise as safe treatments to protect against the side effects of radiation therapy.
Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
11 citations
,
January 2020 in “Micro and Nanosystems” The new gel improves skin delivery of a drug, potentially reducing dose frequency and side effects.
February 2026 in “Revista Eletrônica Polidisciplinar Voos.” A balanced approach using dutasteride and Serenoa repens can improve hair transplant success by protecting follicles and minimizing side effects.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
The patch effectively promotes hair growth for alopecia areata without pain.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
October 2023 in “Microorganisms” Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
2 citations
,
January 2020 in “Brazilian Journal of Veterinary Medicine/Revista Brasileira de Medicina Veterinária” Sarolaner effectively treated feline demodicosis in a cat.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.